Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung08
2021-002555-10Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darunavir + cobicistat and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival. Started Feb 2022; status: active.
02
Drugs
darunavir + cobicistatpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-002555-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002555-10.